Soligenix Announces Reverse Stock Split

Core Points - Soligenix, Inc. plans to implement a reverse stock split at a ratio of 1-for-16, effective June 5, 2024, with trading on a split-adjusted basis starting June 6, 2024 [1][3] - The reverse stock split was approved by stockholders, allowing the Board of Directors to determine the specific ratio within a range of 1-for-2 to 1-for-20 [2] - Following the split, the number of outstanding shares will decrease from approximately 15.8 million to about 987,490 shares, with adjustments made for fractional shares [4] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs [5] - The company is advancing its product HyBryte™ (SGX301) for cutaneous T-cell lymphoma and has completed a second Phase 3 study, seeking regulatory approvals for commercialization [5] - Other development programs include treatments for psoriasis, inflammatory diseases, and a ricin toxin vaccine candidate, supported by government funding [6]